Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

doi:10.1126/science.aaa1348

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Science (New York, N.Y.) - 3 Apr 2015

Rizvi Naiyer A, Hellmann Matthew D, Snyder Alexandra, Kvistborg Pia, Makarov Vladimir, Havel Jonathan J, Lee William, Yuan Jianda, Wong Phillip, Ho Teresa S, Miller Martin L, Rekhtman Natasha, Moreira Andre L, Ibrahim Fawzia, Bruggeman Cameron, Gasmi Billel, Zappasodi Roberta, Maeda Yuka, Sander Chris, Garon Edward B, Merghoub Taha, Wolchok Jedd D, Schumacher Ton N, Chan Timothy A

Abstract excerpt

Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, we used whole-exome sequencing of non-small cell lung cancers treated with pembrolizumab, an antibody targeting programmed cell death-1 (PD-1). In two independent cohorts, higher nonsynonymous mutation burden in tumors was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to CD8-Positive T-Lymphocytes

Share to Disease-Free Survival

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Programmed Cell Death 1 Receptor

Share to Smoking

Source

Open in PubMed Open full text

Identifiers

PMID: 25765070
DOI: 10.1126/science.aaa1348
PMCID: PMC4993154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.PMID 25765070Read ↗

Shedding light on the molecular determinants of response to anti-PD-1 therapy.Semantic proximity Read ↗

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.Semantic proximity Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancerSemantic proximity Read ↗

Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.Semantic proximity Read ↗

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapySemantic proximity Read ↗

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.Semantic proximity Read ↗

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Semantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.